Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation
S. Donaldson, F. Accurso, S. Rowe, J. Clancy, M. Boyle, J. Dunitz, P. Durie, S. Sagel, D. Hornick, M. Konstan, R. Moss, J. Pilewski, R. Rubenstein, A. Uluer, M. Aitken, S. Freedman, L. Rose, N. Mayer-Hamblett, Q. Dong, J. Zha, A. Stone, E. Olson, C. Ordonez, P. Campbell, M. Ashlock, B. Ramsey (Chapel Hill, Aurora, Birmingham, Baltimore, Minneapolis, Iowa City, Cleveland, Palo Alto, Pittsburgh, Philadelphia, Boston, Seattle, Cambridge, Bethesda, United States Of America; , Canada)
Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections
Disease area: Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Donaldson, F. Accurso, S. Rowe, J. Clancy, M. Boyle, J. Dunitz, P. Durie, S. Sagel, D. Hornick, M. Konstan, R. Moss, J. Pilewski, R. Rubenstein, A. Uluer, M. Aitken, S. Freedman, L. Rose, N. Mayer-Hamblett, Q. Dong, J. Zha, A. Stone, E. Olson, C. Ordonez, P. Campbell, M. Ashlock, B. Ramsey (Chapel Hill, Aurora, Birmingham, Baltimore, Minneapolis, Iowa City, Cleveland, Palo Alto, Pittsburgh, Philadelphia, Boston, Seattle, Cambridge, Bethesda, United States Of America; , Canada). Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation. Eur Respir J 2010; 36: Suppl. 54, 359
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease Year: 2011
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
Identification of a novel water-soluble activator of wild-type and F508del CFTR: GPact-11a Source: Eur Respir J 2010; 36: 311 Year: 2010
How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016
CFTR correctors and potentiators: pre-clinical studies in mouse models for CF Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
CFTR dysfunction and its relationship to phenotype and development of new treatments restoring CFTR function Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults Year: 2013
A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium Source: Annual Congress 2011 - Epithelial cells: role in health and disease Year: 2011
Potentiating and correcting mutant CFTR in patients with cystic fibrosis Source: Eur Respir Monogr 2014; 64: 129-149 Year: 2014
Rescue of CFTR function impaired by mutations in exon 15 Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020
A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Allosteric inhibition of the cystic fibrosis transmembrane conductance regulator (CFTR) slows airway mucus transport in normal sheep Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015
A novel CFTR mutation found in a Chinese cystic fibrosis patient Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005
Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease Source: Eur Respir J 2009; 34: 772 Year: 2009